1. Home
  2. EVCM vs NRIX Comparison

EVCM vs NRIX Comparison

Compare EVCM & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EverCommerce Inc.

EVCM

EverCommerce Inc.

HOLD

Current Price

$10.96

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$16.49

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVCM
NRIX
Founded
2006
2009
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.7B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
EVCM
NRIX
Price
$10.96
$16.49
Analyst Decision
Hold
Strong Buy
Analyst Count
8
13
Target Price
$11.50
$29.46
AVG Volume (30 Days)
133.1K
1.3M
Earning Date
03-12-2026
01-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$718,038,000.00
$83,980,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.60
$20.16
P/E Ratio
N/A
N/A
Revenue Growth
22.13
53.95
52 Week Low
$7.66
$8.18
52 Week High
$14.41
$22.50

Technical Indicators

Market Signals
Indicator
EVCM
NRIX
Relative Strength Index (RSI) 38.63 39.80
Support Level $10.40 $16.15
Resistance Level $12.40 $17.50
Average True Range (ATR) 0.65 1.10
MACD -0.20 -0.32
Stochastic Oscillator 22.90 11.87

Price Performance

Historical Comparison
EVCM
NRIX

About EVCM EverCommerce Inc.

EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. With a platform serving approximately 708,000 customers across three core verticals, including numerous micro-verticals, their solutions address diverse needs within these sectors. Revenue is mostly generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty. The majority of customers contribute modest revenue, with a small percentage contributing higher amounts.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: